Detalhe da pesquisa
1.
Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.
Liver Int
; 44(1): 139-147, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37787009
2.
Long-term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.
Am J Gastroenterol
; 2023 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37561058
3.
Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.
Liver Int
; 43(8): 1663-1676, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183524
4.
A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction.
J Viral Hepat
; 28(2): 410-419, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33185325
5.
Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study.
Liver Int
; 41(2): 295-299, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33217778
6.
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
Clin Gastroenterol Hepatol
; 18(11): 2544-2553.e6, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32621971
7.
Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.
Dig Dis Sci
; 64(1): 285-286, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30324553
8.
Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.
Dig Dis Sci
; 63(12): 3487-3497, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30136045
9.
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
J Hepatol
; 66(1): 11-18, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27545497
10.
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
N Engl J Med
; 370(21): 1983-92, 2014 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-24795200
11.
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.
Gastroenterology
; 150(1): 134-144.e10, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26453773
12.
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
J Hepatol
; 64(1): 19-28, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26321288
13.
Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Gastroenterology
; 146(4): 980-8, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24368224
14.
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
Lancet Infect Dis
; 19(3): 275-286, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30833068
15.
Primary peritoneal tuberculosis, a forgotten localization. Case report.
Indian J Tuberc
; 65(3): 257-259, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29933870
16.
Real-Life Use of 3 Direct-Acting Antiviral Regimen in a Large Cohort of Patients with Genotype-1b HCV Compensated Cirrhosis.
J Gastrointestin Liver Dis
; 26(3): 275-281, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28922440
17.
Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
Medicine (Baltimore)
; 96(50): e9271, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29390377
18.
Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial.
Infect Dis Ther
; 5(2): 113-24, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27228998
19.
CccDNA persistence during natural evolution of chronic VHB infection.
Rom J Gastroenterol
; 14(4): 373-7, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16400354
20.
Endocrine dysfunction in sepsis: a beneficial or deleterious host response?
Germs
; 5(1): 17-25, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25763364